Search the Newsreel

Capstone Microturbine For Africa Flare Gas Recovery Project

Capstone Energy+ Inc. is supplying a C600 Signature Series microturbine to Maurel & Prom for a flare gas valorization project in Gabon, West Africa. This project aims to convert gas that would otherwise be flared into electricity for platform operations, with commissioning expected in …

What To Expect From ePlus’s (PLUS) Q2 Earnings

Liquidity Mapping Around (PLUS) Price Events

This article from Stock Traders Daily provides an AI-driven analysis of Eplus Inc. (NASDAQ: PLUS), highlighting strong sentiment across all time horizons. It outlines institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis to guide potential trades. The …

ePlus Number of Employees 2026 | Employee Count & Headcount Data

ePlus, Inc. had approximately 2,155 employees worldwide as of March 2026, marking a 2.8% decline from 2023. The company is actively hiring, with 154 active job postings in 2026, a significant increase from the previous year. Most of its workforce is in the United …

Lazard Asset Management LLC Purchases Shares of 47,854 ePlus inc. $PLUS

Lazard Asset Management LLC recently acquired 47,854 shares of ePlus inc. (NASDAQ:PLUS) for approximately $3.6 million in the first quarter, bringing institutional ownership to 93.8%. Despite the company exceeding quarterly earnings and revenue estimates and increasing its dividend, analyst sentiment remains cautious with a …

Superior Plus Corp. (TSE:SPB) Given Average Recommendation of "Hold" by Brokerages

ePlus (NASDAQ:PLUS) CFO Elaine Marion Sells 2,818 Shares of Stock

ePlus CFO Elaine Marion sold 2,818 shares of the company's stock on July 29th for a total value of approximately $268,330. The company's stock is trading near its 52-week high, and its latest quarterly results exceeded expectations, with EPS of $1.00 and revenue of …

EPLUS Inc (PLUS) CFO sells 2,818 shares under Rule 10b5-1 trading plan

EPLUS Inc. CFO Elaine D. Marion reported selling a total of 2,818 shares of common stock on July 29, 2026, through open-market transactions under a Rule 10b5-1 trading plan. A revocable trust associated with her sold 2,394 shares at a weighted average price of …

(NPCT) Movement as an Input in Quant Signal Sets

The article analyzes Nuveen Core Plus Impact Fund (NASDAQ: NPCT) focusing on its movement as an input in quantitative signal sets. It identifies a neutral sentiment across all horizons with a mid-channel oscillation pattern and outlines specific trading strategies (long, momentum breakout, and short) …

Plus Therapeutics Rebrands to Cerenome, Reflecting Strategic Shift

Plus Therapeutics is rebranding to Cerenome, effective August 3, 2026, and will trade under the new Nasdaq ticker CNSY. This strategic shift transforms the company from a therapeutics-focused entity into an integrated CNS oncology company, combining precision diagnostics, targeted therapeutics, and AI to improve …

Plus500 Ltd. Revenue Breakdown – LSE:PLUS

Plus Therapeutics to trade on Nasdaq as Cerenome under CNSY ticker from Aug. 3

Plus Therapeutics will rebrand to Cerenome and begin trading on the Nasdaq Capital Market under the ticker symbol CNSY starting August 3, 2026. This change will not affect the company's stock listing status or shareholders' ownership interests. The information for this news brief was …

Cerenome Launches as an Integrated CNS Oncology Company

Formerly known as Plus Therapeutics, Cerenome has rebranded to reflect its evolution into an integrated CNS oncology company. The company aims to improve CNS cancer detection, treatment, and understanding by combining precision diagnostics, targeted therapeutics, and artificial intelligence. This strategy includes its CNSide® Diagnostic …

Cerenome will combine CNS cancer diagnostics, treatments and AI Aug. 3

Plus Therapeutics has rebranded as Cerenome, effective August 3, 2026, with its stock trading under the new Nasdaq ticker "CNSY". The company will focus on integrated CNS oncology, combining precision diagnostics (CNSide), targeted therapeutics (REYOBIQ), and an AI-powered data analytics platform. This strategic shift …

Insider Selling: ePlus (NASDAQ:PLUS) COO Sells $182,006.10 in Stock

ePlus COO Darren Raiguel recently sold 1,935 shares of ePlus stock for a total of $182,006.10, reducing his ownership by 2.72% but still retaining a significant stake. The sale occurred despite ePlus exceeding quarterly earnings expectations and increasing its dividend. Analysts, however, currently hold …

ePlus Inc (PLUS) COO’s trust sells 2,000 shares via 10b5-1 plan

Darren S. Raiguel, COO of ePlus Inc (PLUS), reported that a revocable trust for which he and his spouse are trustees sold 2,000 shares of common stock on July 28–29, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted on November …

ePlus (PLUS) to Release Earnings on Tuesday

ePlus (NASDAQ: PLUS) is scheduled to release its Q1 fiscal 2027 earnings after market close on Tuesday, August 4th. Analysts project earnings of $1.19 per share and revenue of $639.95 million. The company recently increased its quarterly dividend to $0.27 per share, while MarketBeat.com …

SLP|Simulations Plus Inc|Price:18.340|Chg%:+0.010

TradingKey provides a comprehensive stock analysis for Simulations Plus Inc (SLP), highlighting its healthy fundamentals, high growth potential, and current "Hold" rating from analysts with an average target price of $19.83. Despite a recent turnaround to a loss, the company's valuation is considered fairly …

Capstone Energy+ to Host First Quarter Fiscal Year 2027 Earnings Conference Call and Webcast on August 12, 2026

Capstone Energy+ Inc. (NASDAQ: CEPL) announced it will host its First Quarter Fiscal Year 2027 earnings conference call and webcast on Wednesday, August 12, 2026, at 1:45 p.m. Pacific Time. The company will release its financial results for the fiscal first quarter ended June …

Dimensional Fund Advisors LP Acquires 48,158 Shares of ePlus inc. $PLUS

Dimensional Fund Advisors LP significantly increased its stake in ePlus inc. (

Simulations Plus Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Simulations Plus, Inc. - SLP

Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Simulations Plus, Inc. (NasdaqGS: SLP) to affiliates of Altaris, LLC for $18.50 per share in cash. KSF is seeking to determine if this consideration and the process leading to it are adequate, …

ePlus inc (PLUS) Valuation: PE, PB & Fair Value Analysis

ePlus inc (PLUS) currently has a valuation score of 8.58, placing it 200th out of 485 companies in the Software & IT Services industry. Its P/E ratio is 18.42, which is significantly below its recent high and above its recent low. Other key valuation …

Plus Therapeutics Market Sentiment

This article provides an overview of market sentiment for Plus Therapeutics Inc. (PSTV), including analyst consensus, short interest trends, and recent insider activities. Four analysts have a "Buy" consensus with a significant average price target upside, though opinions on individual price targets vary widely. …

Rockefeller Capital (PLUS) schedules ePlus stock sales from prior awards

Rockefeller Capital Management has filed a Form 144 notice indicating its intent to sell ePlus (EPLUS) common stock. The filing lists multiple 5,000-share stock awards received as compensation, with award dates ranging from June 2024 to June 2025. This regulatory filing aims to ensure …

EPLUS (PLUS) holder schedules 1,935-share sale valued at $181,905.20

A stockholder associated with Darren S Raiguel plans to sell 1,935 shares of EPLUS (PLUS) common stock through Rockefeller Capital Management on or after July 29, 2026. The planned sale is valued at $181,905.20 and represents a small fraction of the 26,392,561 shares outstanding. …

ePlus stock hits 52-week high at 93.99 USD By Investing.com

ePlus Inc. shares reached a 52-week high of $93.99, marking a 36.73% return over the past year. Despite trading near its high, InvestingPro's Fair Value analysis suggests the stock might be overvalued, though its PEG ratio of 0.66 indicates an attractive valuation relative to …

Fibra Plus presenta sus resultados del segundo trimestre y del primer semestre de 2026

Plus Therapeutics Inc (PSTV) Risk Assessment: Volatility, Financial Risk & Investment Risk

Plus Therapeutics Inc (PSTV) has a risk assessment score of 2.81, ranking 185 out of 384 in the Biotechnology & Medical Research industry. Its beta of 1.41 indicates higher volatility compared to the S&P 500. The article details various risk metrics including maximum drawdown, …

ePlus Inc. (NASDAQ: PLUS) holder plans sale of 65 shares via Rockefeller Capital

An SEC Form 144 filing indicates that the Darren S Raiguel Trust plans to sell 65 common shares of ePlus Inc. (NASDAQ: PLUS) through Rockefeller Capital Management. The aggregate market value of this planned transaction is $6,041.50, with a proposed sale date of July …

Form 144 EPLUS INC For: 28 July By Investing.com

This article announces the filing of Form 144 for EPLUS INC on July 28. It also includes a standard disclaimer from Investing.com about the risks associated with trading in financial instruments and cryptocurrencies. The disclaimer warns that data may not be real-time or accurate …

ePlus will release results after close, webcast starts at 4:30 p.m.

ePlus (NASDAQ: PLUS) announced it will release its first quarter fiscal year 2027 earnings for the three months ended June 30, 2026, after market close on August 4, 2026. A conference call and audio webcast with management will follow at 4:30 p.m. ET. Investors …

EPlus Announces First Quarter Fiscal Year 2027 Earnings Release Date and Conference Call

ePlus inc. (NASDAQ NGS: PLUS) has announced that it will release its first quarter fiscal year 2027 earnings on August 4, 2026, after the market closes. The company will also host a conference call and audio webcast at 4:30 p.m. ET on the same …

Simulations Plus, Inc. Revenue Breakdown – NASDAQ:SLP

Simulations Plus, Inc. (NASDAQ: SLP) generated a total revenue of $79.18 million USD last year. The Software segment was the top performer, contributing $45.83 million USD, an increase from $41.02 million USD in the prior year. The Americas region was the largest contributor to …

Plus Therapeutics to Present New Research at SNO/ASCO Conference

Plus Therapeutics (PSTV) is set to present new research at the 2026 SNO/ASCO CNS Metastases Conference, focusing on their ReSPECT-LM clinical development program and introducing their new brand, Cerenome. The company will also host a symposium on leptomeningeal metastases management and provide updates on …

Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference

Plus Therapeutics, Inc. will present two posters and host a sponsored symposium at the 2026 SNO/ASCO CNS Metastases Conference. The presentations will highlight the Company's REYOBIQ™ clinical development program and CNSide® cerebrospinal fluid diagnostic platform, focusing on improving detection, characterization, treatment, and monitoring of …

First Trust Advisors LP Has $43.57 Million Stock Holdings in ePlus inc. $PLUS

First Trust Advisors LP significantly increased its stake in ePlus inc. (NASDAQ:PLUS) by 118.2% in the first quarter, now holding 579,047 shares valued at $43.57 million. Other institutional investors have also adjusted their positions in the software maker. The article also details ePlus's stock …